CAMBRIDGE, Mass., Sept. 7,
2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:
LPTX), a biotechnology company focused on developing targeted and
immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive
Officer, will participate in a fireside chat at the Baird 2022
Global Healthcare Conference, being held in New York on September
13-14, 2022.
Leap Fireside Chat
Details:
Baird 2022 Global Healthcare Conference
Date: Tuesday, September
13th, 2022
Time: 3:10 p.m. Eastern Time
The fireside chat will be webcast live and may be accessed on
the Investors page of the company's website at
https://investors.leaptx.com/, where a replay of the event will
also be available for a limited time.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing
targeted and immuno-oncology therapeutics. Leap's most advanced
clinical candidate, DKN-01, is a humanized monoclonal antibody
targeting the Dickkopf-1 (DKK1)
protein. DKN-01 is in clinical trials in patients with
esophagogastric, colorectal, and gynecologic cancers. Leap has
entered into a strategic collaboration with BeiGene, Ltd. for the
rights to develop DKN-01 in Asia
(excluding Japan), Australia, and New
Zealand. For more information about Leap Therapeutics, visit
http://www.leaptx.com or view our public filings with the SEC that
are available via EDGAR at http://www.sec.gov or via
https://investors.leaptx.com/.
FORWARD-LOOKING
STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. These statements include
Leap's expectations with respect to the development and advancement
of DKN-01, including the initiation, timing and design of future
studies, enrollment in clinical studies, potential for the receipt
of future option exercise, milestone, or royalty payments from
BeiGene, financial runway, and other future expectations, plans and
prospects. Although Leap believes that the expectations reflected
in such forward-looking statements are reasonable as of the date
made, forward-looking statements are subject to known and unknown
risks, uncertainties and other factors that could cause actual
results to differ materially from our expectations. Such risks and
uncertainties include, but are not limited to: that the initiation,
conduct, and completion of clinical trials, laboratory operations,
manufacturing campaigns, and other studies may be delayed,
adversely affected, or impacted by COVID-19, global conflict or
supply chain related issues; unstable global market and economic
conditions; the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; the
outcome, cost, and timing of our product development activities and
clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective
design or generate positive results; our ability to obtain and
maintain regulatory approval of our drug product candidates; the
size and growth potential of the markets for our drug product
candidates; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates;
and other risks. Detailed information regarding factors that may
cause actual results to differ materially is included in Leap
Therapeutics' periodic filings with the SEC, including Leap's
Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on
March 11, 2022 and as may be updated
by Leap's Quarterly Reports on Form 10-Q and the other reports Leap
files from time to time with the SEC. Any forward-looking statement
contained in this release speaks only as of its date. Leap
undertakes no obligation to update any forward-looking statement
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
matthew@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-the-baird-2022-global-healthcare-conference-301617555.html
SOURCE Leap Therapeutics, Inc.